NCT01294826 - Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Recurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerAdenocarcinoma of the ColonAdenocarcinoma of the Rectum

Interventions

DRUG

AUY922

Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.

DRUG

Cetuximab

Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.

Trial Locations (1)

98104

Swedish Medical Center Cancer Institute, Seattle